MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Decision Cover Letter

Decision of the licensing authority to:

agree a paediatric investigation plan and grant a deferral and grant a waiver

MHRA-100273-PIP03-24

Scope of the Application

Active Substance(s)

Derivative of 6-[2-(pyridin-2- yl)phenoxy]methyl}- 1,2,3,4-tetrahydroisoquinoline

Condition(s)

Treatment of portal hypertension

Pharmaceutical Form(s)

Film-coated tablet; Age-appropriate oral formulation

Route(s) of Administration

ORAL USE

Name / Corporate name of the PIP applicant

Boehringer Ingelheim International GmbH

Basis for the Decision

Pursuant to the Human Medicines Regulations 2012, Boehringer Ingelheim International GmbH submitted to the licensing authority on 08/03/2024 09:39 GMT an application for a Paediatric Investigation Plan

The procedure started on 27/03/2024 17:11 GMT

1. The licensing authority, having assessed the application in accordance with the Human Medicines Regulations 2012, decides, as set out in the appended summary report:

to agree a paediatric investigation plan and grant a deferral and grant a waiver

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This decision is forwarded to the applicant, together with its annex and appendix.

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Final Decision Letter

MHRA-100273-PIP03-24

Of 15/07/2024 11:53 BST

On the adopted decision for Derivative of 6-[2-(pyridin-2- yl)phenoxy]methyl}- 1,2,3,4-tetrahydroisoquinoline (MHRA-100273-PIP03-24) in accordance with the Human Medicines Regulations 2012.

The licensing authority, in accordance with the Human Medicines Regulations 2012, has adopted this decision:

Agreement on a paediatric investigation plan

This decision applies to a Paediatric Investigation Plan for Derivative of 6-[2-(pyridin-2-yl)phenoxy]methyl}- 1,2,3,4-tetrahydroisoquinoline, Film-coated tablet; Age-appropriate oral formulation , ORAL USE .

This decision is addressed to Boehringer Ingelheim International GmbH, Binger Strasse 173, Ingelheim am Rhein, GERMANY, 55216

ANNEX I

1. Waiver

1.1 Condition:

Treatment of portal hypertension The waiver applies / applied to: Paediatric Subset(s): The paediatric population from birth to less than 6 years of age Pharmaceutical form(s): Film-coated tablet Age- appropriate oral formulation Route(s) of administration: ORAL USE Reason for granting waiver: on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments.

2. Paediatric Investigation Plan:

2.1 Condition(s):

Treatment of portal hypertension

2.2 Indication(s) targeted by the PIP:

BI 685509 is indicated for the treatment of clinically significant portal hypertension (CSPH) in paediatric patients with compensated cirrhosis

2.3 Subset(s) of the paediatric population concerned by the paediatric development:

The paediatric population from 6 years to less than 18 years of age

2.4 Pharmaceutical Form(s):

Film-coated tablet Age-appropriate oral formulation.

2.5 Studies:

Study Type	Number of Studies	Study Description
Quality Measures	1	Study 1 Development of an age-appropriate oral formulation suitable for use in children from 6 years of age.
Non-Clinical Studies	0	Not applicable.
Clinical Studies	1	Study 2 (1366-0041) Open-label 52-week study to evaluate dose-exposure and safety of BI 685509 and to explore pharmacodynamic (PD) endpoints in children and adolescents from 6 years to less than 18 years of age with portal hypertension.
Extrapolation, Modeling & Simulation Studies	4	Study 3 Population pharmacokinetic (PK) study optimisation model. Study 4 Population pharmacokinetic (PK) dose-finding model. Study 5 Population PK model and exposure- response investigations. Extrapolation Plan Studies 2, 3, 4 and 5 are part of an extrapolation plan covering the paediatric population from 6 years to less than 18 years of age, as agreed by the Regulatory Agency.
Other Studies	0	Not applicable.
Other Measures	0	Not applicable.

3. Follow-up, completion and deferral of a PIP:

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	31/01/2034
Deferral of one or more studies contained in the paediatric investigation plan:	Yes